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urate nephropathy, acute uric acid nephropathy, and 
uric acid nephrolithiasis which eventually result in 
renal failure.2 
 Increasing concern into this disease was 
brought by the fact that the prevalence of gout 
and hyperuricemia remain large and had risen in 
the past 2 decades.3 During its natural course of 
disease, patients with gout and hyperuricemia are 
also associated with many comorbidities such as 
hypertension, Chronic Kidney Disease (CKD), 
obesity, diabetes, and Myocardial Infarct (MCI) 
probably due to recently found role of uric acid 
in pathogenesis of these comorbidities.4 Several 
studies had been performed in United States, United 
Kingdom, and Germany to estimate the frequency 
of comorbidities in gout population.5,6 However, 
to the best of the author’s knowledge, similiar 
data in Asia, particularly in Indonesia hasn’t been 
documented. To address this issue, this study was 
designed to identify the frequency of comorbidities 
in patients with gout in Rheumatology Clinic 
Dr. Hasan Sadikin General Hospital, Bandung, 
Indonesia.
Methods 
In order to know the pattern of comorbidities in 
patients with gout, cross sectional study using all 
medical records of such patients in Rheumatology 
Clinic Dr. Hasan Sadikin General Hospital were 
carried out. The medical record of a patient would 
be included if the time of admission was between 
January 2012 – December 2013 and the patient 
was diagnosed with gout by attending physician 
or given code as ICD (International Classification 
of Disease) M10. Diagnostic criteria used for 
gout in Rheumatology Clinic Dr. Hasan Sadikin 
General Hospital were based on American College 
of Rheumatology guidelines. Several data were 
recorded for data analysis purpose such as age, 
gender, weight in kilograms, height in centimeters, 
blood pressure at the time of admission, blood 
glucose test (fasting blood glucose, random blood 
glucose, or 2 hours post prandial blood glucose), 
serum creatinine level, and history of myocardial 
infarction. All the data collected were then inserted 
into Microsoft Excel for analysis. Patients without 
any of the data above were excluded
 The presence of particular comorbidites was 
checked according to the following definitions. 
Hypertension was defined as systolic blood pressure 
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Results: Among all patients with gout in Rheumatology 
Clinic Dr. Hasan Sadikin General Hospital, 53.08% had 
chronic kidney disease, 42.73% had hypertension, 
25.39% had diabetes mellitus, 15.70% had myocardial 
infarction and 12.22% had obesity.
Conclusions: Comorbidities commonly found in patients 
with gout in order of frequency were chronic kidney 
disease, hypertension, diabetes mellitus, myocardial 
infarct, and obesity.
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Introduction
Gout is a chronic disease affecting multiple systems 
which is caused by increased serum uric acid 
level (hyperuricemia). This condition contributed 
by error in purine metabolism or excretion is 
commonly further worsened by excessive purine 
intake.1 Hyperuricemia leads to deposition and 
nucleation of uric acid into Monosodium Urate 
(MSU) crystals in synovial space which induces 
an inflammatory reaction and clinically manifested 
as an acute and very painful arthritis commonly 
known as gouty arthritis. Extremely or chronically 
elevated serum uric acid level also can lead to 
several derangements in the renal including chronic 
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more than or equal to 140 mmHg or diastolic pressure more 
than or equal to 90 mmHg.7 Obesity was defined as Body Mass 
Index (BMI) ≥ 30 kg/m2 where BMI is body weight divided 
by height in meters squared.8 Diabetes was defined as either 
fasting blood glucose ≥126 mg/dl or the presence of diabetic 
symptoms (polydipsia, polyuria, polyphagia) and random 
blood glucose ≥200 mg/dl or 2 hours post prandial blood 
glucose ≥200 mg/dL.9 Chronic kidney disease was defined 
as estimated Glomerular Filtration Rate (eGFR) below 60 
ml/min/1.73 m2 where eGFR = ((140-age) × weights (kg)) / 
(72 × serum creatinine).10 History of myocardial infarction 
of each patients is recorded. Patients without the necessary 
data were not included in the data analysis of corresponding 
comorbidities.
Results
There were 128 patients who attended the Rheumatology 
clinic during period January 2012 – December 2013 and 
diagnosed with gout or ICD 10 code M10. Six patients were 
excluded from the data analysis due to the lack of data of 
interest. From these patients, 100 (81.96%) patients were male 
and 22 (18.03%) patients were female. Mean age of patients 
with gout was 58 with standard deviation 11.25 (Table 1).
Table 1 Patients Characteristic
Variable n (%)
Gender
Male 100 (81.96%)
Female 22 (18.03%)
Age 58 (SD 11.25)*
              
* Mean (SD)
There were 5 patients whose data were incomplete for blood 
pressure. Out of 117 patients, 50 patients (42.73%) that 
composed of 40 male and 10 female got hypertension. For 
BMI purpose, there were 32 patients who didn’t have their 
height or weight measured. From 90 patients, 11 patients 
(12.2 %) who consisted of 7 male and 4 female were obese. 
Fifty nine patients got no data about either blood glucose 
measurement or Diabetes history thus weren’t included in 
the analysis of Diabetes.  Among 40 patients which included, 
16 patients (25.39%) consisted of 13 male and 3 female had 
Diabetes. There were 42 patients whose data were incomplete 
for determining eGFR, thus only 81 patients were included 
in the data analysis. From 43 patients (53.08%), there were 
30 men and 6 women suffered from CKD. Coronary Artery 
Disease (CAD) was found in 13 male and 6 female (15.70%) 
out of 121 patients. (Figure 1) 
*Numbers displayed (patients with comorbidities/ all patients 
with particular data regarding the comorbidities)
Figure 1 Comorbidities in Patients with Gout
Discussions
In this study, patients with gout had mean age of 58 (11.25) 
years. Nearly similar data also were presented by Mikuls et 
al. in their study of gout epidemiology that the mean age of 
patients with gout is 60.5 (15.4) years. Male predominance in 
this study, as commonly known in gout patients, was stated in 
that study as well (79.6%). 11
 The most prevalent comorbidity in this study was CKD 
(53.08%) characterized by eGFR <60 ml/min/1.732. Different 
results were presented in studies carried out in United States 
by Zhu et al. in which hypertension (74%) was the leading 
comorbidities in gouty patients in the United States (US) 
while CKD (71%) was the second most.5 Many incomplete 
data in the analysis of CKD frequency could be the factor that 
influencing this discrepancies.  Nevertheless, CKD had strong 
relation with gout based on the knowledge up to now. Kidneys 
act as the main excretory organs of these metabolism end 
products in such way that disturbance in the kidney function 
will decrease uric acid clearance and thus increase serum 
uric acid level.1 Besides that, hyperuricemia could cause a 
downfall in kidneys’ function through urate nephropathy, uric 
acid nephropathy, or nephrolithiasis which terminally lead to 
renal failure.
 Hypertension occurred in 42.73% of patients with gout 
in this study compared with 74%, 17.5%, and 18.5% which 
stated in studies of gout comorbidities in US, United Kingdom 
(UK), and Germany respectively.5,6 These differences occurred 
probably due to the lack of data regarding anti-hypertension 
medication used which probably decrease the number of 
hypertensive patients in this study. Lifestyle variation in 
the population studied also contributed to these variations. 
Nevertheless, increased serum uric acid level is constantly 
associated with hypertension and many data and evidence 
support this. Pathogenesis of hypertension in hyperuricemia 
is related to the biological effects of uric acid in vascular such 
as to decrease Nitric Oxide (NO), increase Reactive Oxygen 
Species (ROS), induce vascular inflammation, and to induce 
proliferation of vascular smooth-muscle cells thus promote to 
vascular narrowing. In addition to vascular effects, uric acid 
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also exerts impacts towards renal such as increased renin, 
decreased NO, interstitial inflammation, interstitial fibrosis 
which all leads to vasoreactive hypertension.4, 12
 Diabetes which occurred in 25.39% of all gout patients 
in this study is concordant with other study in Germany and 
US which was 25.9% and 26% respectively.5,6 Many studies 
had linked hyperuricemia with Diabetes Mellitus. One meta-
analysis study had associated serum uric acid level with the 
risk of developing type 2 Diabetes and found that each 1 mg/
dl increase in serum uric acid resulted in 17% higher risk of 
having type 2 Diabetes Mellitus.13 Uric acid had been found 
as mediator of proinflammatory imbalance in adipose cells by 
inducing ROS production via stimulation of NADPH oxidase 
and decreasing adiponectin production which is an important 
insulin sensitizer and anti-inflammatory substance.14, 15
 Obesity was found in 12.22% patients with gout in this 
study which was smaller in frequency compared with the 
study in US (53%) and UK (27.7%).5,6 This discrepancy 
probably contributed by the lifestyle and socioeconomic level 
differences between the population studied. However, obesity 
had been associated with gout in study by Chen et al. who 
stated that obesity in women and hypertriglyceridemia in men 
could precipitate gout attacks in the absence of saturated serum 
uric acid level.16 It is also proved from the study in the United 
Kingdom general population that obesity was associated with 
higher risk of developing gout.17
 The presence of CAD in 15.7% patients with gout in this 
study also stated by the studies in US, UK, and Germany 
(11.6%,7.4%, and 5.8% respectively).5,6 Relationship 
between gout and coronary artery disease could be explained 
by the effects of uric acid towards vascular which is to 
cause endothelial dysfunction through reduction of NO and 
production of ROS.12 
 The results of this study are consistent with previous study 
carried out in US, UK, and Germany about comorbidities in 
patients with gout such as CKD, hypertension, diabetes mellitus, 
CAD, and obesity even though there were slight differences 
in the results obtained. Data regarding comorbidities of gout 
in Asia are lacking. These discrepancies probably caused by 
the differences in lifestyle and socioeconomic status of the 
population studied. Besides that, the incompleteness of data 
could be one of the factors affecting the differences. This study 
only address the most common comorbidities occurred in gout 
patients, while for the cause and effect relationship between 
gout and its comorbidities or vice versa cannot be determined. 
The results of this study can be used in the future as a step 
for further research about association between gout and its 
comorbidities. The consistent presence of comorbidities 
in patients with gout found in this study necessitates more 
meticulous comprehensive approach to gout management 
through early detection of these reported comorbidities and 
furthermore considering those comorbidities treatments’ 
effects towards serum uric acid level and vice versa.
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